Covance and the Cardio Renal Society of America (CRSA) are pleased to present this third webinar as part of our Cardio Renal Series, co-hosted by Dr. Barbara Gillespie (Therapeutic Head of Nephrology, Covance) and Dr. Peter McCullough (cardiologist and President, CRSA). They will co-host Dr. Katherine Tuttle, an endocrinologist and nephrologist, who has served in leadership positions in both fields and has been involved in many related clinical trials. Drs, McCullough and Tuttle will share their perspectives on the exciting data emerging on SGLT2 inhibitors and the impact on patients with type 2 diabetes mellitus (DM) and chronic kidney disease (CKD). CKD is an under-recognized epidemic, with an estimated global prevalence of 850 million, which is nearly double the global prevalence of DM at 422 million. Nearly half of CKD is attributed to diabetes, and we haven’t seen novel effective therapies for diabetic kidney disease (DKD) since the current standard of care with renal angiotensin aldosterone (RAAS) blockade was established about 18 years ago…until recently.
Dr. Tuttle and Dr. McCullough will share a brief review of SGLT2 inhibitors mechanism of actions & clinical effects, recent trial results and considerations for ongoing trial designs given some gaps in evidence. Since trial results are most meaningful when they can impact patients’ lives, getting SGLT2-I medications into the hands of patients is critical. Therefore, our experts will also discuss the importance of dissemination and implementation of emerging data so we can ensure adaptation of these medications for real-world use.
Barbara S. Gillespie, MD, MMS FASN; Vice President & Therapeutic Head of Nephrology, Covance; Adjunct Professor, University of North Carolina
Dr. Gillespie supports sponsors on renal drug and device development, serves on the Board of Directors at the Kidney Health Initiative, a public-private partnership between the FDA and American Society of Nephrology and participates in several advisory boards and stakeholder panels.
Prior to Covance, Dr. Gillespie worked at Quintiles for 11 years in several leadership roles, and worked on over 15 indications across both CKD and end-stage kidney disease serving as a consultant to sponsors for clinical development plans, due diligence, regulatory submissions, commercialization plans, health economics outcomes research and patient reported outcomes. Her roles also included executive sponsor on a Strategic Partnership and member on a Steering Committee and a Scientific Ad Board.
She is also an associate medical director at a small local dialysis unit, a fellow of the American Society of Nephrology, and received board certification in Internal Medicine in 2004 and in Nephrology in 2006 and 2015.
Peter A. McCullough, MD, MPH, FACP, FACC, FCCP, FAHA, FNKF, FNLA, FCRSA; Founder and current president, Cardio Renal Society of America; Vice Chief of Medicine, Baylor University Medical Center
Dr. McCullough is an internationally recognized authority on the role of CKD as a cardiovascular-risk state with more than 1000 publications and 500 citations in the National Library of Medicine. His works include the “Interface Between Renal Disease and Cardiovascular Illness” in Braunwald’s Heart Disease Textbook.
Dr. McCullough has led observational studies and randomized trials of therapies for acute kidney injury, hypertension, acute coronary syndromes, heart failure and cardiorenal syndromes, as well as chaired and participated on 20 data safety monitoring committees for large randomized trials. He advised sponsors and the FDA resulting in approval of 17 new drugs and 3 novel in vitro diagnostic tests used today around the world.
He serves on the editorial boards of multiple specialty journals, made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, US Food and Drug Administration (FDA), European Medicines Agency, and the US Congressional Oversight Panel.
Katherine R. Tuttle, MD, FASN, FACP, FNKF; Executive Director for Research, Providence Health Care (PHC); Co-Principal Investigator of the Institute of Translational Health Sciences
Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University School of Medicine in Chicago, Illinois. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis, Missouri. Her Nephrology fellowship training was performed at the University of Texas Health Science Center in San Antonio, Texas.
Dr. Tuttle’s major research interests are in the areas of clinical and translational science and precision medicine for diabetes and chronic kidney disease. She has published over 200 original research contributions and served two terms as Associate Editor for each of the Clinical Journal of the American Society of Nephrology and the American Journal of Kidney Disease. Dr. Tuttle served on the Board of Directors for the Kidney Health Initiative and has chaired numerous national and international programs including: National Kidney Foundation – Kidney Disease Outcomes Quality Initiative for Diabetes and Chronic Kidney Disease, National Diabetes Education Program, American Diabetes Association – Diabetes and Chronic Kidney Disease Consensus Conference, National Kidney Foundation Young Investigator Awards, International Society of Nephrology – World Congress of Nephrology, and the Kidney Health Initiative annual program. Dr. Tuttle has received many honors and awards including the Garbed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two Outstanding Clinical Faculty Awards at the University of Washington.
Who Should Attend?
- Medical Affairs
- Project Management
- Regulatory Specialist
- Clinical Operations
- Commercial and Sales
- Chief Medical Officer
- Chief Development Officer
- Medical Director
- Operational Director
- Clinical Development Director
- Clinical Development Manager
- Procurement Manager
What You Will Learn
- Review of SGLT2 inhibitors: mechanism of actions & clinical effects, recent trial results and considerations for ongoing trial designs
- Emerging data on SGLT2 inhibitors and the impact on patients with type 2 DM and CKD
Covance Inc., the drug development business of Laboratory Corporation of America Holdings (LabCorp) headquartered in Princeton, New Jersey, USA, is the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real®.
Our unique perspectives, built from decades of scientific expertise and precision delivery of the largest volume of drug development data in the world, helps our clients identify new approaches and anticipate tomorrow’s challenges as they evolve. Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. Information on Covance’s solutions can be obtained through its website at www.covance.com.